Compare FA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | ARDX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2014 |
| Metric | FA | ARDX |
|---|---|---|
| Price | $11.75 | $6.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $19.00 | $14.67 |
| AVG Volume (30 Days) | 1.2M | ★ 3.8M |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $860,205,000.00 | $2,607,000.00 |
| Revenue This Year | $85.19 | $35.64 |
| Revenue Next Year | $4.90 | $34.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $8.82 | $3.50 |
| 52 Week High | $19.01 | $8.40 |
| Indicator | FA | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 46.75 |
| Support Level | N/A | $5.47 |
| Resistance Level | $14.56 | $6.69 |
| Average True Range (ATR) | 0.76 | 0.35 |
| MACD | 0.09 | -0.10 |
| Stochastic Oscillator | 77.28 | 58.24 |
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.